What are the drug interaction risks and recommended precautions when ketamine is used concurrently with alcohol, opioids, and benzodiazepines or gamma‑hydroxybutyrate (GHB) in adult patients?

Drug Interactions Between Ketamine, Alcohol, Opioids, and Benzodiazepines/GHB

Concomitant use of ketamine with opioids, benzodiazepines, alcohol, or GHB can result in profound sedation, respiratory depression, coma, and death—avoid these combinations whenever possible or use only with intensive monitoring and dose adjustments. 1

Critical Interaction Risks

Ketamine + Opioids

The FDA label explicitly warns that combining ketamine with opioid analgesics may cause:

• Profound sedation
• Respiratory depression
• Coma and death
• Prolonged recovery time from anesthesia 1

Clinical management: When co-administration is unavoidable, closely monitor neurological status and respiratory parameters including respiratory rate and pulse oximetry continuously. Consider individualized dose reductions for both agents. 1

Research demonstrates that ketamine co-administration with fentanyl modestly enhances fentanyl-induced brain hypoxia and potentiates the post-hypoxic oxygen rebound, suggesting synergistic respiratory depressant effects. 2 Poisoning data shows opioid co-use with ketamine increases risk of major adverse effects or death by 2.44-fold. 3

Ketamine + Benzodiazepines

The FDA mandates a black box warning for this combination due to:

• Profound sedation
• Respiratory depression
• Coma and death 4, 1

Clinical management: The 2016 CDC guidelines explicitly state clinicians should avoid prescribing opioids and benzodiazepines concurrently whenever possible, and this principle extends to ketamine combinations. 5 When unavoidable, use the lowest effective doses with continuous cardiorespiratory monitoring.

Special consideration for psychiatric use: Benzodiazepines may significantly dampen ketamine's antidepressant effects. Doses >8mg diazepam equivalent distinguish responders from non-responders with 80% sensitivity and 85% specificity. 6 If using ketamine for depression, consider tapering benzodiazepines beforehand or maintaining doses ≤8mg diazepam equivalent. 7, 6

Ketamine + Alcohol

The FDA label categorizes alcohol as a CNS depressant that may cause profound sedation, respiratory depression, coma, and death when combined with ketamine. 1 The 2022 CDC opioid guidelines emphasize discussing increased respiratory depression risks when CNS depressants like alcohol are used concurrently. 8

Clinical management: Advise patients to completely avoid alcohol during ketamine therapy. Poisoning surveillance data shows alcohol co-use occurs in 10.3% of ketamine exposures. 3

Ketamine + GHB (Gamma-Hydroxybutyrate)

This combination carries the highest risk profile. Poisoning data reveals GHB co-use with ketamine increases risk of major adverse effects or death by 3.43-fold—the highest risk among all drug combinations studied. 3

Mechanism: Ketamine significantly decreases GHB total and metabolic clearance while preventing compensatory respiratory responses. This pharmacokinetic/pharmacodynamic interaction results in:

• Increased GHB exposure
• Prevented compensatory increase in tidal volume
• Significant decline in minute ventilation
• Increased sleep time and lethality 9

Clinical management: This combination should be considered absolutely contraindicated outside of intensive care settings. If overdose occurs, treatment strategies include MCT inhibition (L-lactate or AR-C155858) and GABAB receptor antagonism (SCH50911), but not naloxone. 9

Monitoring Requirements When Co-Administration Is Unavoidable

Mandatory monitoring includes:

• Continuous pulse oximetry
• Respiratory rate every 5-15 minutes
• Blood pressure and heart rate monitoring
• Level of consciousness assessment
• Capnography when available

Risk stratification factors requiring enhanced caution:

• History of prior overdose
• History of substance use disorder (especially alcohol, benzodiazepines, or opioids)
• Respiratory compromise or sleep apnea
• Renal or hepatic dysfunction
• Concurrent use of multiple CNS depressants 10

Harm Reduction Strategies

For all patients receiving ketamine:

1. Prescribe naloxone for opioid co-use scenarios 8, 11
2. Review prescription drug monitoring program (PDMP) data before prescribing 5
3. Educate patients explicitly about respiratory depression risks with CNS depressant combinations 5, 8, 11
4. Secure storage to prevent diversion 8, 11
5. Consider baseline and periodic liver function tests for recurrent ketamine use 1

Common Pitfalls to Avoid

• Do not assume therapeutic ketamine doses are safe with concurrent CNS depressants—the FDA warnings apply to all doses
• Do not dismiss the interaction risk in psychiatric settings where benzodiazepines are commonly prescribed
• Do not overlook polydrug use history when prescribing ketamine—one-third of ketamine poisonings involve co-use 3
• Do not use naloxone for GHB/ketamine overdose—it is ineffective; use GABAB antagonism instead 9